Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology

2019 ◽  
Vol 39 (4) ◽  
pp. 2183-2191 ◽  
Author(s):  
HIDENARI NAGAI ◽  
TAKANORI MUKOZU ◽  
KOJIRO KOBAYASHI ◽  
MAKOTO AMANUMA ◽  
NAOYUKI YOSHIMINE ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Host Immunity ◽  
Advanced Hepatocellular Carcinoma

scholarly journals Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Hidenari Nagai ◽  
Takanori Mukozu ◽  
Daigo Matsui ◽  
Takenori Kanekawa ◽  
Masahiro Kanayama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Liver Cirrhosis ◽  
Antitumor Immunity ◽  
Host Immunity ◽  
Th2 Cells ◽  
Host Immune System ◽  
Advanced Hepatocellular Carcinoma ◽  
Before And After ◽  
Significant Change

Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy.Methods. Forty-five adult Japanese LC patients received sorafenib for aHCC between 2009 and 2011 at our hospital. Sorafenib was administered at a dose of 200–800 mg/day for 4 weeks. Blood samples were collected before and after treatment.Results. Eleven patients were treated with sorafenib at 200 mg/day (200 group), 27 patients received sorafenib at 400 mg/day (400 group), and 7 patients were given sorafenib at 800 mg/day (800 group). There was no significant change in the percentage of Th1 cells after treatment in any group. However, the percentages of Th2 cells and regulatory T cells were significantly decreased after treatment in the 400 group and 800 group compared with before treatment, although there was no significant change after treatment in the 200 group.Conclusions. These results indicate that treatment with sorafenib might induce Th1 dominance and prevent the escape of tumor cells from the host immune system in LC patients with aHCC.

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis

Cancer ◽  
2012 ◽  
Vol 118 (21) ◽  
pp. 5293-5301 ◽  
Author(s):  
Joanne Chiu ◽  
Yuen Fong Tang ◽  
Tzy-Jyun Yao ◽  
Ashley Wong ◽  
Hilda Wong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Single Agent ◽  
Advanced Hepatocellular Carcinoma

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009 ◽  
Vol 43 (5) ◽  
pp. 489-495 ◽  
Author(s):  
Marcus Alexander Wörns ◽  
Arndt Weinmann ◽  
Kerstin Pfingst ◽  
Carla Schulte-Sasse ◽  
Claudia-Martina Messow ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma ◽  
Safety And Efficacy

Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma

2010 ◽  
Vol 66 (6) ◽  
pp. 1123-1129 ◽  
Author(s):  
Hidenari Nagai ◽  
Teppei Matsui ◽  
Masahiro Kanayama ◽  
Kouichi Momiyama ◽  
Kazue Shizawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Combination Chemotherapy ◽  
Advanced Hepatocellular Carcinoma

Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib

2013 ◽  
Vol 73 (2) ◽  
pp. 223-229 ◽  
Author(s):  
Hidenari Nagai ◽  
Takenori Kanekawa ◽  
Kojiro Kobayashi ◽  
Takanori Mukozu ◽  
Daigo Matsui ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

Digestion ◽  
2011 ◽  
Vol 83 (4) ◽  
pp. 275-282 ◽  
Author(s):  
Kerstin Schütte ◽  
Lars Zimmermann ◽  
Jan Bornschein ◽  
Antal Csepregi ◽  
Ricarda Rühl ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Advanced Liver Cirrhosis

Staging of advanced hepatocellular carcinoma patients in the targeted therapy era.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 209-209
Author(s):  
Neeraj Nailesh Shah ◽  
Manal Hassan ◽  
Lianchun Xiao ◽  
James L. Abbruzzese ◽  
Jeffrey Morris ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Targeted Therapy ◽  
Prognostic Index ◽  
Predictive Ability ◽  
Staging System ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
Sorafenib Group ◽  
Staging Systems

209 Background: Several hepatocellular carcinoma (HCC) staging systems are currently available. However, they were all developed before the targeted therapy era prevailed in the last decade which has changed the natural history of the disease. Our study goal was to test the performance of different HCC staging systems in patients with HCC who were treated at our institution during the last decade. Methods: We prospectively enrolled 438 patients from early 2000 to late 2009. Baseline clinicopathologic parameters and staging were available, including the TNM, Cancer of the Liver Italian Program (CLIP), Barcelona Clinic Liver Cancer (BCLC), Okuda, and Chinese University Prognostic Index (CUPI). We performed survival and cox-regression analyses, and compared the staging systems’ predictive ability using Harrell's C-index. Finally, we performed a subgroup analysis of 3 independent cohorts based on whether or not they received sorafenib, whether or not they had hepatitis, and whether or not they had cirrhosis. Results: The overall survival was 13.9 months. Overall, CLIP score was the most predictive staging system with a C-index of 0.71. 187 patients were treated with targeted therapies and 138 were treated with sorafenib after it was approved in 2007. CLIP score was the most predictive staging system with a C-index of 0.71 in the no sorafenib group, and 0.74 in the sorafenib group. In hepatitis patients, CLIP topped amongst all staging systems with a C-index of 0.75, and in patients without hepatitis, despite all staging systems having a poor predictive ability, CLIP score still had the highest C-index of 0.67. Similarly, CLIP score had the best predictive ability in patients with and without pre-existing liver cirrhosis, with C-indices of 0.73 and 0.68 respectively. There was no statistically significant interaction between CLIP score and hepatitis status, and CLIP score and liver cirrhosis. Thus, overall the CLIP score was the best predictive system in all cohorts. Conclusions: Our results suggest that the CLIP score has the highest stratification ability in our advanced HCC patient population, including several subgroups. Our study confirms the utility of the CLIP score to stratify advanced HCC patients in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document